Regulatory Story

RNS Number : 8490A
Shield Therapeutics PLC
03 June 2019

Shield Therapeutics plc

("Shield" or the "Group")


Update on Legal Proceedings


London, UK, 3 June 2019:  Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces an update on legal proceedings with Teva Pharmaceutical Industries Ltd (TEVA).


Following the announcement to shareholders on 14 March 2019, Shield has received notice that TEVA has filed a notice of appeal to the Opposition Division of the European Patent Office's decision on Shield's patent #2 668 175, which covers a "Process for preparing an iron hydroxypyrone".  No date has been set for the hearing.


Shield will continue to robustly defend its intellectual property and believes the Board of Appeal should uphold the first instance decision of the European Patent Office.


Shield will provide further updates to shareholders on proceedings as required.

- Ends -


For further information please contact:


Shield Therapeutics plc

Carl Sterritt, Chief Executive Officer

+44 (0)20 7186 8500

Tim Watts, Chief Financial Officer

Nominated Advisor and Joint Broker

Peel Hunt LLP

James Steel/Dr Christopher Golden                                                

+44 (0)20 7418 8900

Joint Broker

finnCap Ltd

+44 (0)20 7220 0500

Geoff Nash /Matt Radley/ Alice Lane                                    

Financial PR & IR Advisor

Walbrook PR

+44 (0)20 7933 8780 or

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001


About Shield Therapeutics plc

Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs.  The Company's clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron deficiency in adults which has exclusive IP rights until the mid-2030s.  Feraccru® is commercialised in the European Union by Norgine BV and the US Food and Drug Administration (FDA) is currently considering a New Drug Application (NDA), with a PDUFA (Prescription Drug User Fee Act) date of 27th July 2019.  For more information please visit 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit